Phase 1 × Intraocular Lymphoma × Lymphoid × Clear all
NCT01815749 2025-10-06

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1 Active not recruiting
30 enrolled
NCT01769222 2024-01-24

Ipilimumab and Local Radiation for Selected Solid Tumors

Stanford University

Phase 1 Terminated
3 enrolled 5 charts
NCT01523223 2023-11-22

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Stanford University

Phase 1 Completed
16 enrolled
NCT01678443 2021-04-02

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Fred Hutchinson Cancer Center

Phase 1 Terminated
2 enrolled 6 charts
NCT01643603 2020-12-17

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
5 enrolled
NCT01609816 2020-03-16

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Barbara Ann Karmanos Cancer Institute

Phase 1 Terminated
8 enrolled
NCT00049712 2019-12-13

Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

University of Wisconsin, Madison

Phase 1 Completed
NCT00005639 2019-01-11

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
34 enrolled
NCT00005092 2018-10-26

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
7 enrolled
NCT02168907 2018-07-02

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Wake Forest University Health Sciences

Phase 1 Terminated
1 enrolled
NCT01129193 2018-06-04

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
44 enrolled
NCT01567709 2018-04-11

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
34 enrolled
NCT00889408 2017-12-02

DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
25 enrolled
NCT01254578 2017-09-25

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled
NCT01748721 2016-01-08

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Morphotek

Phase 1 Completed
27 enrolled
NCT02109224 2015-08-20

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

National Cancer Institute (NCI)

Phase 1 Terminated
72 enrolled
NCT01658319 2015-08-13

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Case Comprehensive Cancer Center

Phase 1 Completed
20 enrolled
NCT00608361 2015-07-02

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
80 enrolled
NCT00800150 2015-06-08

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

City of Hope Medical Center

Phase 1 Terminated
6 enrolled
NCT00045500 2015-04-30

UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
NCT00003993 2015-04-29

Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
NCT00019344 2015-04-29

Flavopiridol in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00416923 2015-02-16

Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma

University of California, San Francisco

Phase 1 Completed
10 enrolled
NCT01158274 2014-11-07

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00933985 2014-05-01

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
22 enrolled
NCT01231919 2014-04-29

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
45 enrolled
NCT00101205 2014-02-24

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled
NCT00499811 2014-02-24

Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled
NCT00458731 2014-02-19

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

National Cancer Institute (NCI)

Phase 1 Completed
57 enrolled
NCT01273090 2014-01-30

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Children's Oncology Group

Phase 1 Completed
34 enrolled
NCT00293345 2013-09-30

3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00023816 2013-09-20

Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Unknown
NCT00025129 2013-07-18

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
NCT00049699 2013-07-18

VNP40101M in Treating Patients With Advanced or Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00005021 2013-07-11

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

Fox Chase Cancer Center

Phase 1 Completed
17 enrolled
NCT00003395 2013-06-25

Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00016172 2013-06-18

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00042900 2013-06-05

Pyroxamide in Treating Patients With Advanced Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00073944 2013-05-30

BCX-1777 in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00354185 2013-05-16

PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00348985 2013-05-03

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
55 enrolled
NCT00003368 2013-03-21

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

National Cancer Institute (NCI)

Phase 1 Completed
NCT00004189 2013-02-11

Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
NCT00006221 2013-02-11

BMS-247550 in Treating Patients With Advanced Cancers

National Cancer Institute (NCI)

Phase 1 Completed
54 enrolled
NCT00004241 2013-02-07

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled
NCT00002759 2013-02-05

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
3 enrolled
NCT00003970 2013-01-24

Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled